320 related articles for article (PubMed ID: 25609130)
1. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
[TBL] [Abstract][Full Text] [Related]
2. Dual surrogate markers for rapid prediction of epidermal growth factor receptor mutation status in advanced adenocarcinoma of the lung: A novel approach in resource-limited setting.
Udupa KS; Rajendranath R; Sagar TG; Sundersingh S; Joseph T
Indian J Cancer; 2015; 52(3):266-8. PubMed ID: 26905105
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Thyroid Transcription Factor-1 Expression with
Kim HS; Kim JH; Han B; Choi DR
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30736438
[TBL] [Abstract][Full Text] [Related]
6. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
[TBL] [Abstract][Full Text] [Related]
7. [EGFR mutation analysis in non-small-cell lung cancer : Experience from routine diagnostics].
Tapia C; Savic S; Bihl M; Rufle A; Zlobec I; Terracciano L; Bubendorf L
Pathologe; 2009 Sep; 30(5):384-92. PubMed ID: 19357847
[TBL] [Abstract][Full Text] [Related]
8. The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas.
Shanzhi W; Yiping H; Ling H; Jianming Z; Qiang L
PLoS One; 2014; 9(4):e95479. PubMed ID: 24743427
[TBL] [Abstract][Full Text] [Related]
9. The role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer: An institutional experience.
Sekar A; Gupta N; Rajwanshi A; Chaturvedi R; Singh N; Lal A
Cytopathology; 2017 Oct; 28(5):371-377. PubMed ID: 28730709
[TBL] [Abstract][Full Text] [Related]
10. An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.
Wei WE; Mao NQ; Ning SF; Li JL; Liu HZ; Xie T; Zhong JH; Feng Y; Wei CH; Zhang LT
PLoS One; 2016; 11(12):e0168795. PubMed ID: 27992557
[TBL] [Abstract][Full Text] [Related]
11. Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma.
Kanmaz ZD; Aras G; Tuncay E; Bahadır A; Kocatürk C; Yaşar ZA; Öz B; Özkurt CÜ; Gündoğan C; Çermik TF
Cancer Biomark; 2016; 16(3):489-98. PubMed ID: 27062706
[TBL] [Abstract][Full Text] [Related]
12. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
13. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
[No Abstract] [Full Text] [Related]
14. Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue.
Deftereos G; Sandoval A; Furtado LV; Bronner M; Matynia AP
Hum Pathol; 2020 Mar; 97():52-59. PubMed ID: 31978505
[TBL] [Abstract][Full Text] [Related]
15. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): A report of 106 patients from Kolkata.
Chatterjee K; Ray A; Chattopadhyay B
Indian J Cancer; 2017; 54(1):305-307. PubMed ID: 29199710
[TBL] [Abstract][Full Text] [Related]
16. Sample features associated with success rates in population-based EGFR mutation testing.
Shiau CJ; Babwah JP; da Cunha Santos G; Sykes JR; Boerner SL; Geddie WR; Leighl NB; Wei C; Kamel-Reid S; Hwang DM; Tsao MS
J Thorac Oncol; 2014 Jul; 9(7):947-956. PubMed ID: 24922009
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry Profile Predicts
Li W; Niehaus AG; O'Neill SS
Int J Surg Pathol; 2020 Aug; 28(5):502-506. PubMed ID: 32114861
[TBL] [Abstract][Full Text] [Related]
18. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
[TBL] [Abstract][Full Text] [Related]
19. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer.
Vincenten J; Smit EF; Vos W; Grünberg K; Postmus PE; Heideman DA; Snijders PJ; Meijer G; Kuik J; Witte BI; Thunnissen E
J Thorac Oncol; 2012 Oct; 7(10):1522-7. PubMed ID: 22982653
[TBL] [Abstract][Full Text] [Related]
20. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
